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Patients with malignancies have an increased risk for venous thromboembolisms (VTE), but data on patients with acute leukaemia are
very limited so far. We found VTE in 12% of 455 patients with acute leukaemia, half of which occurred in association with central
venous catheters, with equal risk of ALL and AML.
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Venous thromboembolisms (VTE) may occur in patients with
cancer and cause substantial morbidity and mortality. Since the
first report back in 1868 (Trousseau, 1868), many publications
have dealt with the association of thromboembolic and malignant
diseases (Prandoni et al, 1992; Baron et al, 1998; Sorensen et al,
1998; Sutherland et al, 2002; Deitcher, 2003; Lee et al, 2003;
Murchison et al, 2004; Otten et al, 2004). A recently published
study reported VTE in 7.6% of 1041 patients with solid tumours
(Sallah et al, 2002), whereas we found VTE in 7.7% of 1038 patients
with malignant lymphoma with a higher incidence in high-grade
than in low-grade lymphoma (Mohren et al, 2005). Data on
patients with acute leukaemia have been scarce until very recently.
However, an increased standardised incidence ratio of preceding
VTE has been noticed in AML among other malignancies (White
et al, 2005).
Otherwise frequent complications of acute leukaemia include
thrombocytopenia-associated bleeding and granulocytopenia-
related severe infection. Thus, thromboembolic complications
have so far received little attention. As we observed coincidently
VTE especially related to central venous catheters in a small
number of consecutive leukaemia patients, we decided to initiate
this retrospective study.
PATIENTS AND METHODS
Medical records of all patients with acute leukaemia treated in our
institution between January 1992 and April 2005 were reviewed.
Patients with acute lymphoblastic and acute myeloid leukaemia as
well as CML blast crisis (BC) according to the WHO 1997 criteria
(Harris et al, 1999) were included in this study. Patients with
myelodysplastic syndrome, myeloproliferative disease or CLL were
excluded from the analysis. Venous thromboembolisms was
confirmed either by venography or duplex ultrasound (deep vein
thrombosis, central venous catheter-associated thrombosis),
CT-scan or scintigraphy (pulmonary embolism) or by fundoscopy
(central vein thrombosis). Superficial thrombophlebitis or central
venous catheter occlusions without thrombosis were not counted
as a VTE. Data were collected and analysed in a microsoft excel
database.
STATISTICAL ANALYSIS
P-values to show correlation of VTE with leukaemia lineage,
patient age and gender were obtained using Fisher’s exact test. All
reported P-values are two-sided. As only one of 37 patients with
blast crises had VTE, this patient group was not included in further
correlation analysis.
RESULTS
A total of 455 patients with acute leukaemia were eligible for
analysis. In total, 248 patients (55%) were male, 207 were female
(45%) and median age was 60 years. A total of 310 patients had
AML (68%), 108 had ALL (24%) and 37 (8%) had BC (Table 1). Of
the 310 patients with AML 89 (28.7%) had secondary leukaemia
and only seven of the remaining 221 patients (3.2%) had
promyelocytic leukaemia (PML) that is frequently associated with
disseminated intravascular coagulation and/or hyperfibrinolysis.
Among patients with PML, three had VTE: one patient had
CVC-associated VTE after her third chemotherapy (cytarabine and
idarubicine) course. She had been in complete haematological
remission and was not taking ATRA at that time. The other two
patients with PML had deep vein thrombosis during follow-up
while still in complete remission.
There were 55 patients (12.1%) with at least one VTE. Venous
thromboembolisms included central venous catheter-associated
venous thrombosis in 27 patients (5.9%) and 28 non-central
venous catheter-associated VTE (6.2%) (Table 2). The latter
comprised deep vein thrombosis (n¼20), upper extremity deep
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svein thrombosis (n¼2), pulmonary embolism (n¼5), thrombosis
of the inferior caval vein (n¼1) and central vein thrombosis
(n¼1). Only one patient had deep vein thrombosis on first
presentation of ALL (lymphocytic blasts 45G/l, platelets 265G/l),
whereas the great majority of VTE occurred during therapy (82%).
The overall VTE rate was equal in ALL and AML (P¼1.0).
However, patients with ALL were less likely to develop central
venous catheter-associated venous thrombosis than patients with
AML, although the difference failed to reach statistical significance
(P¼0.119). In two of 10 patients with ALL (20%) and non-central
venous catheter-associated VTE, deep venous thrombosis occurred
in association with the use of asparaginase. There was no
difference in the VTE rate in male vs female patients with acute
leukaemia (P¼0.193) (Table 3), but patients younger than 60 years
had a higher risk for VTE than patients of 60 years or more
(P¼0.014), attributed to a higher incidence of central venous
catheter-associated venous thrombosis (P¼0.003). There was no
statistically significant difference in the rate of non-central venous
catheter-associated VTE between both age groups (P¼0.563)
(Table 4). Only one patient with BC had a VTE.
DISCUSSION
In this retrospective analysis, we found VTE in 12.1% of patients
with acute leukaemia, a rate that is even higher than recently
reported numbers from patients with other malignancies such as
solid tumours or malignant lymphomas. No difference was found
between AML and ALL. Central venous catheter-associated
thrombosis were particularly common, accounting for half of all
VTE in this cohort of leukaemia patients, whereas deep vein
thrombosis and/or pulmonary embolisms were responsible for
the other half of VTE. The rate of non-central venous catheter-
associated thrombosis of 6.2% is very similar to those found in
other malignancies (Sallah et al, 2002; Mohren et al, 2005).
The higher overall VTE rate in patients younger than 60 years in
our study is due to the high incidence of central venous catheter-
associated venous thrombosis in this patient group. This finding
was made owing to the larger number of inserted central venous
catheters in young patients, older patients often experiencing a
very dismal prognosis and rather receiving palliative treatment
rather than aggressive chemotherapy.
Only two very recently published studies have dealt with the
association of VTE and acute leukaemia: in an observational
cohort study of 379 acute leukaemia patients, 3.4% had VTE as a
presenting manifestation and further 3.2% developed VTE within
6 months after diagnosis of leukaemia (de Stefano et al, 2005).
Patients with ALL receiving L-asparaginase were at particularly
high risk. A retrospective Austrian study looked at the incidence of
VTE in close temporal relationship to the onset of acute leukaemia
in 719 patients and found a VTE rate of 2.1% with equal risk in
AML and ALL (Ziegler et al, 2005). Both studies found a high rate
of VTE at first presentation in patients with PML, an AML subtype
that is frequently associated with either bleeding or thrombosis
(Dally et al, 2005). In contrast to these findings, none of our
patients with this AML subtype had VTE on diagnosis of
leukaemia. However, three of seven patients with PML (42%) in
our cohort developed VTE later during the course, when leukaemia
was no longer present, rather a coincidental finding than a true
association. Surprisingly, only 3.2% of patients in our cohort had
PML, a lower than expected number.
In comparison to both previous studies, we observed a higher
overall rate of VTE. This may be partially due to the longer
observation period in our retrospective study. Ziegler et al
investigated acute leukaemia associated VTE in close temporal
relationship with diagnosis of the leukaemia only and de Stefano
et al reported an observation period of 6 months after disease
onset. However, since half of the VTE occurring in our patient
cohort were associated with the use of central venous catheters,
this complication is most likely responsible for the substantially
higher VTE rate observed in our analysis. Our reported rate of
non-central venous catheter-associated thrombosis of 6.2% is
comparable to the VTE rate observed by de Stefano et al, although
we failed to find a statistically significant difference between AML
and ALL.
A high rate of central venous catheter-associated thrombosis of
12–15% in patients with haematological malignancies including
acute leukaemia has been reported in two previous studies from
Italy, and these numbers are similar to those reported from non-
thrombocytopenic patients with central venous catheter-associated
thrombosis (Cortelezzi et al, 2003, 2005). Since the authors
counted superficial thrombophlebitis as a venous thromboembolic
event and not all our patients had a central venous catheter
inserted, no direct comparison of the central venous catheter-
associated thrombosis rates observed in the studies by Cortelezzi
Table 1 Patients with acute leukaemia: total number and distribution
according to leukaemia type and patient gender
All patients Male patients Female patients
(n)( % ) ( n) (%) (n) (%)
Acute leukaemia 455 100 248 54.5 207 45.5
AML 310 68.1 160 51.6 150 48.3
ALL 108 23.7 65 60.1 43 39.8
BC 37 8.1 23 62.1 14 37.8
Table 2 Patients with acute leukaemia (AL) and VTE: analysis according
to leukaemia type and presence of a central venous catheter (CVC)
Total VTE CVC-associated VTE Non-CVC-associated VTE
(n)( % ) ( n)( % ) ( n)( % )
AL 55 12.1 27 5.9 28 6.2
AML 40 12.9 23 7.4 17 5.5
ALL 14 13.0 4 3.7 10 9.3
BC 1 2.7 0 — 1 2.7
Table 3 VTE in patients with AL according to age and gender
VTE (n) VTE (%)
AgeX60 Jahre (n¼229) 19 8.3
Age o60 Jahre (n¼226) 26 15.9
Male (n¼248) 25 10.1
Female (n¼207) 30 14.5
Table 4 Central venous catheter (CVC)-associated and non-CVC-
associated VTE in patients with acute leukaemia according to age
AgeX60 years Ageo60 years
n % n %
CVC-associated VTE 6 2.6 21 9.3
Non-CVC-associated VTE 13 5.7 15 6.6
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set al with our data is possible. However, these findings are
supporting evidence that central venous catheter-associated
thrombosis is responsible for a considerable number of throm-
boses in patients with acute leukaemia.
We conclude that VTE are frequent in patients with acute
leukaemia; thus, prophylactic measures even in thrombocytopenic
patients need to be established, particularly in patients with central
venous catheters.
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